RxDoctor Payments Data

Leslie Nelson, MD

Internal Medicine · Desoto, TXNPI 1700826088

Payments from drug & device makers

$14,914in general payments, 2019–2025

Across 45 payments — averaging $331.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis Pharma AG$14K
  • Novo Nordisk$440
  • Abbott$133
  • Lilly USA, LLC$121
  • Biogen$116
  • GSK$27
  • plus $82 from 5 others
$14in research payments, 2019–2025

Across 1 payment — averaging $14.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$14

What the payments were for

  • Travel & lodging$13,99494%
  • Food & beverage$9196%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,914 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$72,304
Medicare patients
208
Services billed
834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide183$177,274
JardianceEmpagliflozin92$124,783
RybelsusSemaglutide67$98,505
EliquisApixaban32$44,733
FarxigaDapagliflozin Propanediol31$42,516
JanuviaSitagliptin Phosphate24$38,875
TradjentaLinagliptin30$38,707
TrulicityDulaglutide16$35,049
MounjaroTirzepatide34$32,837
LinzessLinaclotide20$27,416
Tresiba Flextouch U-200Insulin Degludec32$21,217
MyrbetriqMirabegron17$17,964
WegovySemaglutide13$17,339
Tresiba Flextouch U-100Insulin Degludec29$13,584
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$13,507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$440$293,118263 claims
Boehringer IngelheimJardiance, Tradjenta$24$163,490122 claims
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30$121$69,60862 claims
MerckJanuvia$11$38,87524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Desoto

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →